News Releases and Articles
01/22/2009
DiaKine Drug
Improves type 2 Insulin Action; Reduces Harm of Fat in Preclinical Study
(read story)
DiaKine Therapeutics’ Lead Compound in Phase 2 Clinical Trial
(read story)
04/08/2008
DiaKine Combination
Therapy May Hold the Key to Reversing Type 1 Diabetes
(read story)
Key Patent Awarded for DiaKine Therapeutics'
Anti-inflammatory Drugs
(read story)
(read patent)
DiaKine Therapeutics
and AdPharma to Develop Diabetes Inhibiting Drugs
DiaKine Therapeutics
and Mediatech to Market Immune Modulating Media Designed to Improve
Islet Cell Transplants
12/01/2005
Diakine Therapeutics - Emerging Company Profile - Start-Up Magazine
10/19/2005
Emerging Diabetes Start-Up DiaKine Raising First
Institutional Round - Dow Jones VentureWire
08/24/2005
UVa Researchers Find that LSF Potentially
Could Reduce Heart Disease in the Metabolic Syndrome
06/13/2005
Lisofylline in Combination with Exendin-4
Reverses Diabetes in a Type 1 Model (PDF)
06/01/2005
DiaKine Therapeutics Acquires Investigational New Drug Application for
Lisofylline (PDF)
03/29/2005
Keith D.
Ignotz Named President and CEO of Diabetes Pharmaceutical Company
DiaKine Therapeutics (PDF)
01/04/2005
Cell Therapeutics, Inc. (CTI) Licenses Lisofylline and Related Patent
Portfolio to DiaKine Therapeutics, Inc. for Development in Diabetes (PDF)
Documents in PDF format require the Free Adobe Reader
|
